Castle Biosciences (CSTL) Share-based Compensation (2018 - 2026)

Castle Biosciences (CSTL) has 9 years of Share-based Compensation data on file, last reported at $9.8 million in Q1 2026.

• Quarterly Share-based Compensation fell 12.55% year-over-year to $9.8 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $44.5 million (down 8.88% YoY) and the FY2025 annual result came in at $45.9 million, down 8.8% from the prior year.
• Share-based Compensation fell to $9.8 million in Q1 2026 per CSTL's latest filing, from $11.4 million in the prior quarter.
• The five-year high for Share-based Compensation was $13.5 million in Q1 2023, with the low at $8.4 million in Q1 2022.
• Average Share-based Compensation over 5 years is $11.4 million, with a median of $11.4 million recorded in 2024.
• Year-over-year, Share-based Compensation soared 84.28% in 2022 and retreated 14.96% in 2025.
• Castle Biosciences' Share-based Compensation stood at $9.9 million in 2022, then advanced by 18.94% to $11.8 million in 2023, then dropped by 3.08% to $11.4 million in 2024, then dropped by 0.29% to $11.4 million in 2025, then retreated by 14.29% to $9.8 million in 2026.
• Business Quant data shows CSTL's Share-based Compensation at $9.8 million in Q1 2026, $11.4 million in Q4 2025, and $12.1 million in Q3 2025.